中国临床药理学杂志2025，Vol.41Issue(6)：862-865,4.DOI:10.13699/j.cnki.1001-6821.2025.06.021
用LC-MS/MS法测定非小细胞肺癌患者血浆中伏美替尼浓度
Determination of furmonertinib in non-small cell lung cancer patients plasma by LC-MS/MS
摘要
Abstract
Objective To devolope a liquid chromatography-tandem mass spectrometry(LC-MS/MS)method for the determination of furmonertinib in human plsama and apply this method to analyze the blood concentration of non-small cell lung cancer(NSCLC)patients after taking medicine.Methods Furmonertinib-d3 was employed as the internal standard.The analyte and internal standard were extracted from plasma by protein precipitation with acetonitrile and chromatographed on Agilent Poroshell 120 SB-C18(2.1 mm×100.0 mm,3.5 μm);mobile phase consisted of acetonitrile-10 mmoL-1 ammonium acetate(both of containing 0.1％formic acid);the whole analytical time was 3 min.The quantitative analysis were ionized with an electrospray ionization(ESI)source and operated in positive ion,multiple reaction monitoring(MRM)mode,the specificity,linear range,precision and accuracy,extraction recovery rate,matrix effect,dilution validation,and stability were all investigated.Results The standard curves were demonstrated to be liner in the range of 0.50-100.00μg·L-1 with y=3.95×10-2x-4.16×10-4(r=0.995 4).The accuracy was 95.8％-107.3％.The coefficient of variation(CV)of inter-day(n=6)and intra-day(n=3)for four different concentration levels were less than 15％.The average recoveries and matrix effects were between 83.1％-88.2％and 94.6％-105.8％.Conclusion The established LC-MS/MS method for determining the concentration of vormetinib meets the requirements of biological sample analysis and can be used for the concentration determination of vormetinib in clinical practice.关键词
伏美替尼/液相色谱-串联质谱/血药浓度Key words
furmonertinib/liquid chromatography-tandem mass spectrometry/plasma concentration分类
医药卫生引用本文复制引用
程敏毓,李力,沈琦,羊红玉..用LC-MS/MS法测定非小细胞肺癌患者血浆中伏美替尼浓度[J].中国临床药理学杂志,2025,41(6):862-865,4.基金项目
浙江省中医药科技计划基金资助项目(2023ZL213) （2023ZL213）
